#4577 RENAL SAFETY OF FLOT REGIMEN FOR GASTROESOPHAGEAL CANCER

Abstract Background and Aims Currently, peri-operative docetaxel, oxaliplatin, leucovorin, 5-fluorouracil (FLOT) chemotherapy is the gold standard treatment for patients with locally advanced gastric cancer (LAGC), who undergo surgery. The known nephrotoxicity of both docetaxel oxaliplatin compounds may limit its application in CKD population. Nevertheless, limited evidence available regarding effects FLOT regimen on renal function. In our analysis we evaluated safety LAGC Method Retrospective data patient resectable four tertiary referral hospital between jan/2018 to jan/2022 have been analyzed. Patient treated (60 mg/m2), (85 leucovorin (200 (2,600 mg/m2 as a 24 hr infusion), all given day 1 administered every 2 weeks 4 administrations before Serum creatinine, hemoglobin, lymphocytes CKD-EPI eGFR were detected at baseline each cycle. AKI onset/prevalence determined according K-DIGO criteria. Results A consecutive cohort 90 was enrolled. At present 16 pts (21.9%). Median 84,9 ml/min. terms decay onset during cycle, result ANOVA indicated no significant differences or relationship FLOT; Wilks’ Lambda = 0.94, p 0.354 (Table Figure 1). incidence very low one episode stage (0,7%) 2nd 4th New anemia 1st cycle only adverse event observed (p 0.003). Conclusion According results, pre-operative seems negligible impact function rate toxicity suggesting possibility extend use even CKD.